Evidence map›Paper›PMID 36959803›Full record

ArticleFrontiers in oncology2023

A bibliometric study of the top 100 most-cited papers in neuroendocrine prostate cancer.

Yu Gan, Qiangrong He, Chao Li, Bassam Lutf Mohammed Alsharafi, Hengfeng Zhou, Zhi Long

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu GanDepartment of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Qiangrong HeAndrology Center, Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chao LiAndrology Center, Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Bassam Lutf Mohammed AlsharafiAndrology Center, Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hengfeng ZhouAndrology Center, Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhi LongAndrology Center, Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study used bibliometrics to define and analyze the characteristics of the first 100 most cited papers on the topic of neuroendocrine prostate cancer (NEPC). Methods: We explored the Web of Science Core Collection database, and screened the top 100 most frequently cited articles and reviews with the title NEPC or small cell prostate cancer (SCPC). We conducted bibliometrics research on the screening results to identify the most influential journals and authors in the field of NEPC. Results: The first 100 most cited papers have been cited a total of 14,795 times, from 73 to 833 times (mean ± standard deviation, 147.95 ± 101.68). All top 100 most cited papers were published from 1984 to 2019, and the total number of citations for papers published in 2016 was significantly higher than that for papers published in other years. The journal with the largest number of published papers is "Prostate" (n=8). "Neuroendocrine differentiation" has become the most frequently used author keyword. "Oncology" is the most popular topic in the field of NEPC. Conclusion: We analyzed the first 100 most cited papers in the NEPC field by collecting detailed information, which provide guiding opinions for finding the most influential journals and authors in NEPC-related fields. We hope to help researchers and readers in this field improve their understanding of NEPC research trends and provide ideas for future research from a unique perspective.

Indexed as

bibliometric studyneuroendocrine differentiationneuroendocrine prostate cancersmall cell prostate cancertop 100

Identifiers

PMID36959803
PMCPMC10027713

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read3
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.